MediWound Ltd. (NASDAQ:MDWD) Receives Consensus Rating of “Hold” from Brokerages

MediWound Ltd. (NASDAQ:MDWD) has received an average rating of “Hold” from the four ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $35.00.

Several equities research analysts recently issued reports on MDWD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Wall Street Zen lowered MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th.

Institutional Investors Weigh In On MediWound

Large investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in MediWound in the fourth quarter worth $26,000. BNP Paribas Financial Markets increased its position in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the period. Russell Investments Group Ltd. increased its position in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the fourth quarter worth $109,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Trading Up 3.8%

MDWD stock opened at $17.26 on Tuesday. The firm has a market cap of $221.79 million, a P/E ratio of -8.22 and a beta of 0.21. MediWound has a 12-month low of $14.90 and a 12-month high of $22.50. The stock’s 50 day simple moving average is $17.00 and its 200 day simple moving average is $17.72.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million for the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. On average, research analysts forecast that MediWound will post -2.75 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.